Crinetics Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

• Crinetics Pharmaceuticals Inc CRNX.OQ reported a quarterly adjusted loss of 96 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of thirteen analysts for the quarter was for a loss of 91 cents per share. Wall Street expected results to range from $-1.03 to -74 cents per share.

• Reported revenue was zero​; analysts expected $240.00 thousand.

• Crinetics Pharmaceuticals Inc's reported EPS for the quarter was a loss of 96 cents​.

• The company reported a quarterly loss of $76.83 million.

• Crinetics Pharmaceuticals Inc shares had risen by 15.0% this quarter and gained 65.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is 70.00

This summary was machine generated from LSEG data November 13 at 02:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)